1. Zuo Quan#, Song Xinyi#, Yan Jie#, Bao Guangjun, Li Yiping, Shen Jieting, He Zeyuan, Hu Kuan*, Sun Wangsheng*, Wang Rui*. Triazination/IEDDA Cascade Modular Strategy Installing Pyridines/Pyrimidines onto Tyrosine Enables Peptide Screening and Optimization. Journal of the American Chemical Society 2025; 147: 9576-9589.(IF=15.7)
2. Zhang Siqi#, Ma Xiaohui#, Wu Jiang#, Shen Jieting, Shi Yuntao, Wang Xingkai, Xie Lin, Sun Xiaona, Wu Yuxuan, Tian Hao, Gao Xin, Chen Xueyao, Huang Hongyi, Chen Lu, Song Xuekai, Hu Qichen, Zhang Hailong, Wang Feng*, Jin Zhao-Hui*, Zhang Ming-Rong*, Wang Rui*, Hu Kuan*. Enhanced radiotheranostic targeting of integrin α5β1 with PEGylation-enabled peptide multidisplay platform (PEGibody): A strategy for prolonged tumor retention with fast blood clearance. Acta Pharmaceutica Sinica B 2025; 15: 692-706.(IF=14.6)
3. Wang Kun#, Wang Ke#, Wang Cong, Yang Hange, Zhou Gangzhong, Ji Peihong, Sun Xudong, Chen Gong, Fan Xuegong, Hu Kuan*, Yi Juan*, Zhang Hailong*, Wang Rui*. Development of Dual-Receptor Lysosome-Targeting Chimeras for Protein Degradation. Journal of the American Chemical Society 2025.(IF=15.7)
4. Cheng Xueting#, Jiang Shuo#, Peng Xingtong#, Yang Pan#, Zhang Siqi, Xu Chaoying, Gao Xin, Fan Shihui, Liu Hongtan, Zhuang Jie, Chen Xueyao, Liang Naixin, Lin Bingni, Lu Qingshuang, Chen Meirong, Xiao Yibei*, Zhu Zhaohui*, Wang Rui*, Hu Kuan*, Wu Chuanliu. Multicyclic Peptides Targeting PD-L1 for Radiotheranostics: From Discovery to Clinical Proof-of-Concept. Journal of the American Chemical Society 2025; 147: 35638-35654(IF=15.7)
5. He Zhongshan#, Chen Wei#, Hu Kuan#, Luo Yaoyao, Zeng Wanqin, He Xi, Li Tingting, Ouyang Jiang, Li Yongjiang, Xie Lin, Zhang Yiding, Xu Qin, Yang Shuping, Guo Mengran, Zou Wei, Li Yanfei, Huang Lingjing, Chen Lu, Zhang Xingcai, Saiding Qimanguli, Wang Rui, Zhang Ming-Rong, Kong Na, Xie Tian, Song Xiangrong*, Tao Wei*. Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment. Nature Nanotechnology 2024; 19: 1386-1398.(IF=38.1)
6. Xie Lin#, Zhang Lulu#, Hu Kuan#, Hanyu Masayuki, Zhang Yiding, Fujinaga Masayuki, Minegishi Katsuyuki, Ohkubo Takayuki, Nagatsu Kotaro, Jiang Cuiping, Shimokawa Takashi, Ashisuke Kazuma, Okonogi Noriyuki, Yamada Shigeru, Wang Feng, Wang Rui, Zhang Ming-Rong. A 211At-labelled mGluR1 inhibitor induces cancer senescence to elicit long-lasting anti-tumor efficacy. Cell Reports Medicine 2023; 4: 100960.(IF=11.7)
7. Hu Kuan#, Wu Wenyu#, Xie Lin, Geng Hao, Zhang Yiding, Hanyu Masayuki, Zhang Lulu, Liu Yinghuan, Nagatsu Kotaro, Suzuki Hisashi, Guo Jialin, Wu Yundong*, Li Zigang*, Wang Feng*, Zhang Mingrong*. Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors. Acta Pharmaceutica Sinica B 2022; 12: 1363-1376.(IF=14.5)
8. Hu Kuan, Xie Lin, Zhang Yiding, Hanyu Masayuki, Yang Zhimin, Nagatsu Kotaro, Suzuki Hisashi, Ouyang Jiang, Ji Xiaoyuan, Wei Junjie, Xu Hao, Farokhzad Omid C., Liang Steven H. *, Wang Lu*, Tao Wei*, Zhang Ming-Rong*. Marriage of black phosphorus and Cu2+ as effective photothermal agents for PET-guided combination cancer therapy. Nature Communications 2020; 11: 2778.(IF=14.9)
9. Hu Kuan#, Jiang Yixiang#, Xiong Wei, Li Hu, Zhang Pei-Yu, Yin Feng, Zhang Qianling, Geng Hao, Jiang Fan*, Li Zhou*, Wang Xinwei*, Li Zigang*. Tuning peptide self-assembly by an in-tether chiral center. Science Advances 2018; 4: eaar5907.(IF=11.5)
10. Hu Kuan, Geng Hao, Zhang Qingzhou, Liu Qisong, Xie Mingsheng, Sun Chengjie, Li Wenjun, Lin Huacan, Jiang Fan, Wang Tao*, Wu Yun-Dong*, Li Zigang*. An In-tether Chiral Center Modulates the Helicity, Cell Permeability, and Target Binding Affinity of a Peptide. Angewandte Chemie International Edition 2016; 55: 8013-8017. (IF=11.4)